Withdrawal for any reason (medium term: treatment duration from 5 to 8 weeks) · people with chemotherapy‐induced nausea and vomiting
It is very uncertain whether cannabinoids changes withdrawal any reason ( compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with chemotherapy‐induced nausea and vomiting
It is very uncertain whether cannabinoids changes withdrawal due to adverse event ( compared with placebo (very low certainty).
1 finding from 1 review
Absence of nausea ( · people with chemotherapy‐induced nausea and vomiting
Cannabinoids showed no clear difference in absence of nausea ( compared with other anti‐emetic agent (low certainty).
1 finding from 1 review
Absence of vomiting ( · people with chemotherapy‐induced nausea and vomiting
Cannabinoids showed no clear difference in absence of vomiting ( compared with other anti‐emetic agent (moderate certainty).
1 finding from 1 review
Absence of nausea and vomiting ( · people with chemotherapy‐induced nausea and vomiting
Cannabinoids showed no clear difference in absence of nausea and vomiting ( compared with other anti‐emetic agent (low certainty).
1 finding from 1 review
Overall mortality · people with chemotherapy‐induced febrile neutropenia
Benefits and harms of CSF plus antibiotics showed no clear difference in overall mortality compared with antibiotics alone (low certainty).
1 finding from 1 review
Infection‐related mortality · people with chemotherapy‐induced febrile neutropenia
Benefits and harms of CSF plus antibiotics showed no clear difference in infection‐related mortality compared with antibiotics alone (low certainty).
1 finding from 1 review
People hospitalized for > 10 days · people with chemotherapy‐induced febrile neutropenia
Benefits and harms of CSF plus antibiotics may leads to lower people hospitalized for > 10 days compared with antibiotics alone (low certainty).
1 finding from 1 review
Duration of grade IV neutropenia (lower values signify better outcomes) · people with chemotherapy‐induced febrile neutropenia
Benefits and harms of CSF plus antibiotics showed no clear difference in duration of grade IV neutropenia (lower values signify better… compared with antibiotics alone (low certainty).
1 finding from 1 review
Time to recovery from fever (lower values signify better outcomes) · people with chemotherapy‐induced febrile neutropenia
Benefits and harms of CSF plus antibiotics showed no clear difference in time to recovery from fever (lower values signify better outcomes) compared with antibiotics alone (low certainty).
1 finding from 1 review
Time to withdrawal from ATB (lower values signify better outcomes) · people with chemotherapy‐induced febrile neutropenia
Benefits and harms of CSF plus antibiotics showed no clear difference in time to withdrawal from ATB (lower values signify better outcomes) compared with antibiotics alone (low certainty).
1 finding from 1 review
Deep vein thrombosis · people with chemotherapy‐induced febrile neutropenia
Benefits and harms of CSF plus antibiotics showed no clear difference in deep vein thrombosis compared with antibiotics alone (low certainty).
1 finding from 1 review
Documented PCP infections Clinical and microbiological criteria · patients with Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients
1 finding from 1 review
All‐cause mortality ‐ sensitivity analysis · patients with Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients
TMP/SMX showed no clear difference in all cause mortality ‐ TMP/SMX versus placebo or no treatment compared with placebo, no treatment or non‐PCP drug (low certainty).
1 finding from 1 review
PCP‐related mortality Clinical only · patients with Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients
TMP/SMX may leads to lower PCP‐related mortality Clinical only compared with placebo, no treatment or non‐PCP drug (low certainty).
1 finding from 1 review
Adverse events: severe adverse events requiring treatment discontinuation ‐ TMP/SMX versus placebo or no treatment Clinical and laboratory criteria and treatment discontinuations · patients with Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients
TMP/SMX showed no clear difference in adverse events: severe adverse events requiring treatment… compared with placebo, no treatment or non‐PCP drug (moderate certainty).
1 finding from 1 review
Intervention not reported
3‐year overall survival rate (37.2/40.2 mo) · women with locally advanced uterine cervix cancer
The intervention showed no clear difference in 3‐year overall survival rate (37.2/40.2 mo) (low certainty).
1 finding from 1 review
Intervention not reported
Locaregional recurrence · women with locally advanced uterine cervix cancer
The intervention showed no clear difference in locaregional recurrence (moderate certainty).
1 finding from 1 review
Intervention not reported
Distant metastasis · women with locally advanced uterine cervix cancer
The intervention showed no clear difference in distant metastasis (moderate certainty).
1 finding from 1 review
Intervention not reported
5‐year overall survival rate (3 to 6 yr) · women with locally advanced uterine cervix cancer
The intervention showed no clear difference in 5‐year overall survival rate (3 to 6 yr) (low certainty).
1 finding from 1 review